Femasys Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
$FEMY
Medical/Dental Instruments
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 13, 2025
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
(770 ) 500-3910
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
| Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
On October 13, 2025, Daniel Currie, Chief Operating Officer of Femasys Inc. (the “Company”) informed the Company of his decision to retire from the
Company, effective as of December 15, 2025. Mr. Currie will remain in his current role with the Company until his departure.
Mr. Currie’s decision to retire follows more than 20 years of dedicated service, having joined the Company in March 2004, and is based on personal health
considerations, a desire to focus on family and the next chapter of his life.
In connection with his planned retirement, on October 16, 2025, the Company and Daniel Currie entered into a Separation and General Release Agreement
(the “Separation Agreement”).
Under the terms of the Separation Agreement:
| • |
Any outstanding equity awards will be treated as follows: unvested stock options will vest through the retirement date.
|
| • |
Health benefits will continue under COBRA through December 31, 2026, with Company contributions consistent with current coverage levels.
|
| • |
The Separation Agreement includes a general release of claims, as well as non-competition, non-solicitation, and confidentiality covenants customary for such
agreements.
|
The Company and Board of Directors extend their sincere appreciation to Mr. Currie for his more than 20 years of leadership and service and wish him the
very best in his retirement.
| Item 9.01. |
Financial Statements and Exhibits.
|
(d) Exhibits
|
Exhibit
|
Description
|
|
|
Separation Agreement
|
||
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Femasys Inc.
|
||
|
By:
|
/s/ Kathy Lee-Sepsick
|
|
|
Names: Kathy Lee-Sepsick
|
||
|
Title: Chief Executive Officer
|
||
|
Date: October 17, 2025
|
||